Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
CORT

CORT - Corcept Therapeutics Inc Stock Price, Fair Value and News

31.72USD-0.92 (-2.82%)Delayed as of 13 Jun 2024, 12:03 pm ET

Market Summary

CORT
USD31.72-0.92
Delayedas of 13 Jun 2024, 12:03 pm
-2.82%

CORT Alerts

  • 4 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

CORT Stock Price

View Fullscreen

CORT RSI Chart

CORT Valuation

Market Cap

3.4B

Price/Earnings (Trailing)

28.79

Price/Sales (Trailing)

6.49

EV/EBITDA

22.94

Price/Free Cashflow

27.25

CORT Price/Sales (Trailing)

CORT Profitability

Operating Margin

99.74%

EBT Margin

26.95%

Return on Equity

21.54%

Return on Assets

17.99%

Free Cashflow Yield

3.67%

CORT Fundamentals

CORT Revenue

Revenue (TTM)

523.5M

Rev. Growth (Yr)

38.95%

Rev. Growth (Qtr)

8.42%

CORT Earnings

Earnings (TTM)

118.0M

Earnings Growth (Yr)

74.83%

Earnings Growth (Qtr)

-11.46%

Breaking Down CORT Revenue

52 Week Range

21.2034.28
(Low)(High)

Last 7 days

-5.2%

Last 30 days

18.6%

Last 90 days

37.9%

Trailing 12 Months

40.0%

How does CORT drawdown profile look like?

CORT Financial Health

Current Ratio

5.18

CORT Investor Care

Shares Dilution (1Y)

2.49%

Diluted EPS (TTM)

1.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024523.5M000
2023413.8M428.2M450.0M482.4M
2022380.2M392.0M397.6M401.9M
2021340.1M343.1M352.9M366.0M
2020334.9M351.2M356.0M353.9M
2019258.4M268.4M285.4M306.5M
2018189.3M216.0M237.7M251.2M
201792.9M108.7M129.7M159.2M
201656.2M64.0M72.5M81.3M
201532.2M38.4M44.3M50.3M
201413.0M17.0M21.7M26.6M
20135.0M6.0M7.6M10.4M
20122.4M2.7M3.0M3.3M
2011001.8M2.1M
20100566.0K1.0M1.5M
2009000101.0K
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Corcept Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 04, 2024
robb gary charles
acquired
46,060
3.29
14,000
chief business officer
Jun 04, 2024
robb gary charles
sold (taxes)
-268,679
32.87
-8,174
chief business officer
Jun 03, 2024
lyon joseph douglas
sold (taxes)
-14,723
30.17
-488
see remarks
Jun 03, 2024
maduck sean
sold (taxes)
-24,829
30.17
-823
see remarks
Jun 03, 2024
guyer william
acquired
192,600
19.26
10,000
chief development officer
Jun 03, 2024
lyon joseph douglas
acquired
38,561
15.65
2,464
see remarks
Jun 03, 2024
mokari atabak
acquired
45,322
15.65
2,896
chief financial officer
Jun 03, 2024
mokari atabak
sold (taxes)
-17,227
30.17
-571
chief financial officer
Jun 03, 2024
robb gary charles
sold (taxes)
-21,843
30.17
-724
chief business officer
Jun 03, 2024
lyon joseph douglas
sold
-150,916
30.1832
-5,000
see remarks

1–10 of 50

Which funds bought or sold CORT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
added
18.75
-153
886
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
-57,000
184,000
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
-225,000
780,000
0.01%
May 28, 2024
Verity Asset Management, Inc.
sold off
-100
-234,213
-
-%
May 24, 2024
Cetera Investment Advisers
new
-
908,049
908,049
-%
May 22, 2024
BURNEY CO/
added
2.96
-2,743,820
10,873,000
0.41%
May 20, 2024
CIM, LLC
added
0.82
37,679
397,473
0.06%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-4.52
-768,196
2,191,710
-%
May 16, 2024
COMERICA BANK
reduced
-12.51
-388,942
821,069
-%
May 16, 2024
Ancora Advisors LLC
new
-
362,434
362,434
0.01%

1–10 of 38

Are Funds Buying or Selling CORT?

Are funds buying CORT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CORT
No. of Funds

Unveiling Corcept Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 27, 2024
ingalls & snyder llc
8.0%
8,262,476
SC 13G/A
Feb 14, 2024
baker g leonard jr
5.3%
5,512,696
SC 13G/A
Feb 13, 2024
renaissance technologies llc
6.52%
6,725,871
SC 13G/A
Feb 13, 2024
vanguard group inc
9.25%
9,537,532
SC 13G/A
Feb 12, 2024
belanoff joseph k
6.1%
6,581,918
SC 13G/A
Jan 22, 2024
blackrock inc.
15.9%
16,407,696
SC 13G/A
Feb 17, 2023
ingalls & snyder llc
6.6%
7,090,370
SC 13G/A
Feb 15, 2023
belanoff joseph k
5.5%
6,081,918
SC 13G/A
Feb 14, 2023
baker g leonard jr
5.1%
5,485,196
SC 13G/A
Feb 13, 2023
renaissance technologies llc
6.77%
7,288,871
SC 13G/A

Recent SEC filings of Corcept Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 06, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 03, 2024
144
Notice of Insider Sale Intent
Jun 03, 2024
144
Notice of Insider Sale Intent
Jun 03, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Corcept Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
56.6B
6.8B
17.55% 15.42%
-9.49
8.27
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.1B
2.0B
6.10% -19.49%
-60.58
10.04
75.20% 68.82%
16.1B
2.5B
5.03% -10.77%
78.14
6.5
13.74% 186.89%
13.5B
3.8B
4.06% -3.24%
18.05
3.57
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.63% 71.22%
-9.82
48.09
54.84% -28.31%
5.2B
524.1M
-1.19% -54.45%
-12.36
9.84
394.93% 39.61%
3.4B
251.0M
-5.41% -4.45%
-11.47
13.54
73.58% -86.73%
3.2B
240.7M
16.82% -26.89%
-6.77
12.77
-1.03% -213.92%
2.5B
813.8M
1.25% -38.59%
-1.5K
3.12
56.43% 98.83%
2.2B
996.6M
20.98% 97.26%
-5.59
2.23
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-4.75% 32.39%
28.02
4.44
60.38% -34.49%
547.7M
881.7K
19.55% 492.49%
-16.22
481.06
-77.61% 33.36%
245.6M
4.2M
-16.55% 51.92%
-1.97
59.05
-66.30% 48.24%
22.0M
2.1M
40.11% 239.32%
-0.95
7.61
-13.45% 69.54%

Corcept Therapeutics Inc News

Latest updates
Seeking Alpha11 Jun 202404:08 pm
StockNews.com06 Jun 202403:25 pm

Corcept Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue8.4%14713512411810610310210394.0099.0096.0092.0079.0086.0086.0089.0093.0088.0082.0072.0065.00
Costs and Expenses13.1%11710492.0088.0091.0081.0070.0072.0067.0062.0060.0060.0060.0055.0062.0053.0056.0053.0049.0048.0046.00
  S&GA Expenses19.3%56.0047.0045.0043.0049.0042.0035.0038.0038.0032.0031.0030.0030.0026.0027.0026.0028.0027.0024.0025.0024.00
  R&D Expenses6.9%59.0055.0046.0043.0041.0037.0033.0033.0028.0029.0028.0028.0029.0028.0034.0026.0026.0024.0023.0022.0020.00
EBITDA Margin4.3%0.27*0.26*0.25*0.26*0.26*0.29*0.33*0.33*0.35*0.34*0.34*0.32*---------
Income Taxes32.5%7.005.005.005.003.008.00-1.605.004.005.006.006.00-3.605.004.008.009.007.008.006.002.00
Earnings Before Taxes-4.9%35.0037.0036.0033.0018.0024.0033.0032.0027.0037.0036.0032.0020.0031.0025.0036.0039.0036.0034.0026.0020.00
EBT Margin4.4%0.27*0.26*0.25*0.25*0.26*0.29*0.32*0.34*0.35*0.34*0.34*0.32*---------
Net Income-11.5%28.0031.0031.0028.0016.0017.0035.0027.0023.0032.0030.0027.0023.0026.0022.0028.0030.0029.0026.0020.0018.00
Net Income Margin2.5%0.23*0.22*0.20*0.22*0.23*0.25*0.29*0.29*0.29*0.31*0.30*0.28*---------
Free Cashflow303.5%24.006.0053.0042.0026.0033.0033.0018.0035.0049.0049.0044.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets5.5%656622594525618583533496468424585568552572534498445412367329320
  Current Assets9.8%503459432433534499452419388266402411410479463438345307267233217
    Cash Equivalents10.5%15013611217230066.0050.0035.0062.0078.0095.0095.0052.0076.0031.0059.0084.0031.0045.0058.0050.00
  Inventory-7.0%7.008.008.007.006.006.006.005.005.005.005.005.005.005.005.005.005.005.005.005.005.00
  Net PPE-34.9%0.000.000.000.000.001.001.001.001.001.001.001.001.002.001.001.001.001.001.001.001.00
Liabilities-5.9%10811513210388.0082.0060.0054.0060.0048.0045.0046.0042.0048.0044.0044.0036.0041.0033.0031.0034.00
  Current Liabilities-7.0%97.0010512293.0079.0072.0053.0049.0057.0048.0045.0045.0041.0047.0043.0042.0034.0039.0032.0030.0034.00
Shareholder's Equity8.1%548507462422530502473442408376540523511523490454409371334298286
  Retained Earnings6.9%43040337134031229628024521819516313210682.0056.0035.007.00-23.55-52.94-79.28-99.46
  Additional Paid-In Capital2.7%758739722696680662649626609591571554536516496482466457447437427
Shares Outstanding-0.6%103103104102108108107106106116116116---------
Float----1,827---2,058---2,122---1,633---1,071-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations303.5%23,7565,88752,90942,28625,95733,38833,64818,04035,24749,42748,70444,33925,42235,07130,44453,18633,26948,45438,42725,55523,681
  Share Based Compensation1.4%13,24913,06512,87611,85811,14110,52110,55410,60610,76110,81010,95211,06810,1018,4308,7028,4897,9187,6107,2717,7366,696
Cashflow From Investing-152.7%-9,01417,098-109,570-24,097207,475-17,241-4,790-41,800-50,496140,471-25,80324,742-3,28411,220-64,273-85,94419,734-61,989-54,316-1,156-367
Cashflow From Financing-170.9%-543766-3,916-145,754181-61.00-13,961-2,756-506-206,969-23,643-26,032-45,947-6615,8666,804205-1442,696-15,908-15,289
  Buy Backs-476--145,428------25,77429,17033,5419,670--275--17,42013,555
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CORT Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]  
Product revenue, net$ 146,808$ 105,654
Operating expenses:  
Cost of sales2,5351,386
Research and development58,50540,851
Selling, general and administrative56,26848,564
Total operating expenses117,30890,801
Income from operations29,50014,853
Interest and other income5,4933,581
Income before income taxes34,99318,434
Income tax expense(7,231)(2,555)
Net income27,76215,879
Net income attributable to common stockholders, basic27,51415,807
Net income attributable to common stockholders, diluted$ 27,514$ 15,807
Basic net income per share (in dollars per share)$ 0.27$ 0.15
Diluted net income per share (in dollars per share)$ 0.25$ 0.14
Weighted-average shares outstanding used in computing net income per common share  
Basic (in shares)102,791107,885
Diluted (in shares)109,915115,425

CORT Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 149,750$ 135,551
Short-term marketable securities261,011232,670
Trade receivables, net of allowances61,51841,123
Insurance recovery receivable related to Melucci litigation (Note 4)014,000
Inventory7,1907,730
Prepaid expenses and other current assets23,89827,562
Total current assets503,367458,636
Strategic inventory7,8468,244
Operating lease right-of-use asset61120
Property and equipment, net127195
Long-term marketable securities40,27657,176
Other assets6,3886,541
Deferred tax assets, net97,87090,605
Total assets655,935621,517
Current liabilities:  
Accounts payable12,55717,396
Accrued research and development expenses24,82521,330
Accrued and other liabilities59,74451,628
Accrued settlement related to Melucci litigation (Note 4)014,000
Short-term operating lease liability76151
Total current liabilities97,202104,505
Long-term accrued income taxes payable10,86910,307
Total liabilities108,071114,812
Commitments and contingencies (Note 4)
Stockholders’ equity:  
Preferred stock00
Common stock133133
Treasury stock(641,059)(635,078)
Additional paid-in capital758,244738,515
Accumulated other comprehensive income258609
Retained earnings430,288402,526
Total stockholders’ equity547,864506,705
Total liabilities and stockholders’ equity$ 655,935$ 621,517
CORT
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
 CEO
 WEBSITEcorcept.com
 INDUSTRYBiotechnology
 EMPLOYEES299

Corcept Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Corcept Therapeutics Inc? What does CORT stand for in stocks?

CORT is the stock ticker symbol of Corcept Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Corcept Therapeutics Inc (CORT)?

As of Wed Jun 12 2024, market cap of Corcept Therapeutics Inc is 3.4 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CORT stock?

You can check CORT's fair value in chart for subscribers.

What is the fair value of CORT stock?

You can check CORT's fair value in chart for subscribers. The fair value of Corcept Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Corcept Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CORT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Corcept Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CORT is over valued or under valued. Whether Corcept Therapeutics Inc is cheap or expensive depends on the assumptions which impact Corcept Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CORT.

What is Corcept Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 12 2024, CORT's PE ratio (Price to Earnings) is 28.79 and Price to Sales (PS) ratio is 6.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CORT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Corcept Therapeutics Inc's stock?

In the past 10 years, Corcept Therapeutics Inc has provided 0.296 (multiply by 100 for percentage) rate of return.